Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | RECQL | P46063 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | PPARD | Q03181 | 12/20 | 0.44 |
| ▸ | PPARA | Q07869 | 5/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | PPARG | P37231 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.39 |
| ▸ | AGER | Q15109 | 1/20 | 0.39 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5613384 | 0.86 | PPARD (0.55) | MTNR1APPARDPPARAPPARGFFAR1 | |
| SCHEMBL5613930 | 0.85 | PPARA (0.50) | MTNR1APPARDPPARAPPARG | |
| SCHEMBL5613730 | 0.83 | PPARD (0.45) | PPARDPPARAPPARGPTPN1FFAR1 | |
| SCHEMBL5613728 | 0.79 | PPARD (0.65) | SMN1; SMN2PPARDPPARAPPARGFFAR1 | |
| SCHEMBL5613508 | 0.79 | PPARA (0.59) | SMN1; SMN2PPARDPPARAPPARGFFAR1 | |
| SCHEMBL4950019 | 0.75 | PPARD (0.61) | PPARDPPARA | |
| SCHEMBL5606596 | 0.75 | PPARD (0.45) | TSHRPPARDPPARAPPARGKDM4E | |
| SCHEMBL4953686 | 0.74 | PPARD (0.58) | PPARDPPARAPPARG | |
| SCHEMBL5606352 | 0.74 | PPARD (0.47) | PPARDPPARAPPARGAGER | |
| SCHEMBL4956335 | 0.74 | PPARD (0.58) | PPARDPPARAPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1749000-A2 | BICYCLIC, SUBSTITUTED TRIAZOLES AS MODULATORS OF PPAR AND METHODS OF THEIR PREPARATION | METABOLEX, INC. (US) | 2007-02-07 | — | — | EP | claimed |
| US-20060014785-A1 | BICYCLIC, SUBSTITUTED TRIAZOLES AS MODULATORS OF PPAR AND METHODS OF THEIR PREPARATION | METABOLEX, INC. (US) | 2006-01-19 | — | — | US | claimed |
| WO-2005115384-A2 | BICYCLIC, SUBSTITUTED TRIAZOLES AS MODULATORS OF PPAR AND METHODS OF THEIR PREPARATION | METABOLEX, INC. (US) | 2005-12-08 | — | — | WO | claimed |
| EP-1749000-A2 | BICYCLIC, SUBSTITUTED TRIAZOLES AS MODULATORS OF PPAR AND METHODS OF THEIR PREPARATION | METABOLEX, INC. (US) | 2007-02-07 | — | — | EP | disclosed |
| US-20060014785-A1 | BICYCLIC, SUBSTITUTED TRIAZOLES AS MODULATORS OF PPAR AND METHODS OF THEIR PREPARATION | METABOLEX, INC. (US) | 2006-01-19 | — | — | US | disclosed |
| WO-2005115384-A2 | BICYCLIC, SUBSTITUTED TRIAZOLES AS MODULATORS OF PPAR AND METHODS OF THEIR PREPARATION | METABOLEX, INC. (US) | 2005-12-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060014785-A1 | BICYCLIC, SUBSTITUTED TRIAZOLES AS MODULATORS OF PPAR AND METHODS OF THEIR PREPARATION | PPARG, PPARD, GPR119 | MTNR1A 1335/4885TP53 2848/4885RECQL 3988/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.